China: Hitgen Aims to Strengthen its “Innovation Foundation”…
PharmaBoardroom had the pleasure of interviewing HitGen chairman & CEO Dr Jin LI in July regarding the company’s focus on DNA-encoded chemical…
Tagged with HitGen
Chinese Biotech Strategies: Biologics or Small Molecules
While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception…
Jin LI – Chairman & CEO, HitGen, China
Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the…
China Pharma News Roundup May 11th 2020
Top recent news from Chinese pharma, including listings on the Hong Kong Stock Exchange, Junshi's out-licensing of a potential COVID-19 treatment to…
